ACTG Adds First Polyclonal Antibody to ACTIV-2 Outpatient Treatment Study for COVID-19

Retrieved on: 2021-04-21 19:52:30

Tags for this article:

Click the tags to see associated articles and topics

ACTG Adds First Polyclonal Antibody to ACTIV-2 Outpatient Treatment Study for COVID-19. View article details on hiswai:

Excerpt

AZD7442 (AstraZeneca): a combination of two monoclonal antibodies being studied as both a 15-minute infusion and an intramuscular injection ...

Article found on: www.newswise.com